Bridion (Sugammadex Sodium) Patent Expiration, LOE Window & CMS Spending

Bridion (Sugammadex Sodium) by Merck & Co.: FDA Orange Book core substance LOE 2026-07-27 (last listed 2028-06-12), 0 AB generics, $34.9M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN022225 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-07-27
Last Listed Patent or Exclusivity Date2028-06-12
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$34.9M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$34.9M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.